United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2012_register executive 2012-01-24 article Notices D09002ee1c7fda42b D09002ee1c7fda4ac United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license, subject to existing non-exclusive licenses and current non-exclusive license applications under consideration, to practice the inventions embodied in U.S. Provisional Patent Application No. 61/405,668 and PCT Patent Application No. PCT/US2011/057272 and foreign equivalents thereof entitled "Anti-MAGE-A3 T cell receptors and related materials and methods of use" (HHS Ref. No. E-236-2010/0); U.S. Provisional Patent Application No. 61/384,931 and PCT Patent Application No. PCT/US2011/051537 and foreign equivalents thereof entitled "Anti-SSX-2 T cell receptors and related materials and methods of use" (HHS Ref. No. E-269-2010/0); U.S. Provisional Patent Application No. 61/473,409 entitled "Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer" (HHS Ref. No. E-148-2011/0); and U.S. Provisional Patent Application No. 61/535,086 entitled "T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted MAGE-A" (E-266-2011/0) to Kite Pharma, Inc., which is located in Los Angeles, California. The patent rights in these inventions have been assigned to the United States of America. Other than license applications submitted as objections to this Notice of Intent to Grant an Exclusive License, no further license applications will be considered for the exclusive field of use set forth below if Kite Pharma, Inc. is granted an exclusive license pursuant to this Notice of Intent to Grant an Exclusive License. The prospective exclusive license territory may be worldwide and the field of use may be limited to the treatment of cancers, which may include brain cancer, breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, liver cancer, lung cancer, melanoma, multiple myeloma, ovarian cancer, prostate cancer, sarcoma, and urothelial cancer, as claimed in the Licensed Patent Rights. 77 FR 3482 https://www.govinfo.gov/app/details/FR-2012-01-24/2012-1383 2012-1383 fr24ja12-59 4140-01-P https://www.govinfo.gov/app/details/FR-2012-01-24/2012-1383 https://www.govinfo.gov/content/pkg/FR-2012-01-24/html/2012-1383.htm https://www.govinfo.gov/content/pkg/FR-2012-01-24/pdf/2012-1383.pdf 1 p. 3482 3482 77 FR 3482 Prospective Grant of Exclusive License: Development of T Cell Receptors and Chimeric Antigen Receptors Into Therapeutics for Adoptive Transfer in Humans To Treat Cancer; Federal Register Vol. 77, Issue NOTICE 2012-1383 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2012-02-23 4140-01-P 2012-1383 Notice.

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license, subject to existing non-exclusive licenses and current non-exclusive license applications under consideration, to practice the inventions embodied in U.S. Provisional Patent Application No. 61/405,668 and PCT Patent Application No. PCT/US2011/057272 and foreign equivalents thereof entitled "Anti-MAGE-A3 T cell receptors and related materials and methods of use" (HHS Ref. No. E-236-2010/0); U.S. Provisional Patent Application No. 61/384,931 and PCT Patent Application No. PCT/US2011/051537 and foreign equivalents thereof entitled "Anti-SSX-2 T cell receptors and related materials and methods of use" (HHS Ref. No. E-269-2010/0); U.S. Provisional Patent Application No. 61/473,409 entitled "Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer" (HHS Ref. No. E-148-2011/0); and U.S. Provisional Patent Application No. 61/535,086 entitled "T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted MAGE-A" (E-266-2011/0) to Kite Pharma, Inc., which is located in Los Angeles, California. The patent rights in these inventions have been assigned to the United States of America. Other than license applications submitted as objections to this Notice of Intent to Grant an Exclusive License, no further license applications will be considered for the exclusive field of use set forth below if Kite Pharma, Inc. is granted an exclusive license pursuant to this Notice of Intent to Grant an Exclusive License. The prospective exclusive license territory may be worldwide and the field of use may be limited to the treatment of cancers, which may include brain cancer, breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, liver cancer, lung cancer, melanoma, multiple myeloma, ovarian cancer, prostate cancer, sarcoma, and urothelial cancer, as claimed in the Licensed Patent Rights.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 23, 2012 will be considered, in addition to the current non- exclusive applications under consideration, for the prospective license territory and field of use to be granted under the contemplated exclusive patent license. Prospective Grants of Exclusive Licenses: Development of T Cell Receptors and Chimeric Antigen Receptors into Therapeutics for Adoptive Transfer in Humans to Treat Cancer , bishse@mail.nih.gov Vol. 77, no. 15 Office of the Federal Register, National Archives and Records Administration 2012-01-24 continuing daily deposited born digital 198 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2012-01-24 P0b002ee181b8ff65 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr24ja12 https://www.govinfo.gov/app/details/FR-2012-01-24 https://www.govinfo.gov/content/pkg/FR-2012-01-24/pdf/FR-2012-01-24.pdf https://www.govinfo.gov/content/pkg/FR-2012-01-24/xml/FR-2012-01-24.xml fdlp 3367 3558 DGPO 2012-01-24 2024-06-03 FR-2012-01-24 machine generated eng FR FR-2012-01-24 77 15